Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

I.a

I - Interstitial/parenchymal lung disease

Pneumonitis (ILD)

Last update 17/06/2026

Or 'ILD'. (Fr: PnP subaiguë). A.k.a. pulmonary infiltrates. Generally bilateral and symmetrical. Gradual onset. Consistent with but not specific for an NSIP-c pattern on pathology. Less- dense, severe, acute and diffuse than pattern Ia. Lacks the features of ARDS that may accompany pattern Ia. Can be in the form of disseminated linear, reticulonodular, miliary or patchy opacities. BAL is indicated to separate this pattern from PIE (Ic) or DAH (IIIa). Acute chest pain can be at the forefront. A search for microorganisms including Pneumocystis (stains, PCR) is indicated. On pathology (although not many cases undergo a confirmatory lung biopsy), there is interstitial inflammation and a more or less dense cellular interstitial cellular infiltrate (NSIP-c). Fibrosis, alveolar edema and/or a reactive epithelium denote those cases resulting from with antineoplastic chemotherapy agents. The frontier between patterns Ia and I b can be difficult to draw, so please check drugs under both Ia and Ib. Patients may quickly shift from pattern Ib to Ia particularly if the the causal drug is inappropriately continued. Prompt withdrawal must be considered, underlying disease permitting, and can be therapeutic.

Causative drugs

435

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Abemaciclib
I.a
I.b
I.c
II.e
XIX.a
Abiraterone
I.a
I.b
II.b
X.t
XII.a
XII.ak
Acebutolol
I.a
I.e
IV.a
IV.b
VI.a
VI.c
VI.d
X.aa
Acyclovir
I.a
VI.a
Adagrasib
I.a
I.b
Adalimumab
I.a
I.b
I.c
I.e
I.g
I.n
I.x
I.aa
II.e
III.a
III.d
IV.a
VI.d
VI.m
IX.j
X.b
X.d
X.e
X.l
X.m
X.u
XII.a
XII.s
XVI.e
XVI.k
XIX.a
XIX.d
XIX.f
XX.a
XX.b
XX.c
XX.e
XX.f
XX.g
XX.y
XX.z
Ado-trastuzumab emtansine
I.a
I.b
I.c
I.d
II.h
II.v
VII.b
Afatinib
I.a
IV.x
VI.a
X.l
XII.q
XVI.b
XIX.aq
Albuferon (albinterferon)
I.a
I.b
Alectinib
I.a
I.e
I.i
I.ap
VI.a
XII.c
XVIII.a
XIX.a
XXIII.e
Alemtuzumab
I.a
I.b
II.a
II.e
III.a
IV.a
VII.b
X.e
X.i
X.m
X.ae
X.ap
XIX.a
XIX.o
XX.b
XX.e
XX.h
XX.m
XXI.b
Alk inhibitors
I.a
I.b
I.e
II.e
XII.q
XVI.a
XVI.b
XVI.k
XIX.a
XIX.d
Alkylating agents
I.a
I.b
I.g
I.y
II.e
VI.p
VII.c
XIX.bd
XIX.br
All-transretinoic acid (ATRA)
I.a
I.l
II.a
II.e
II.h
II.l
III.a
VI.a
VI.m
VII.a
VII.d
X.q
X.ad
XII.c
Almonertinib
I.a
Loading more…